What’s going on with NCNA?
NuCana plc (NCNA) stock was slightly down after the British company sued Gilead Sciences (GILD) in Germany, alleging patent infringement for the sale of Hepatitis C drug Sovaldi and relation combination drugs. NCNA shares were down 2.64% to $4.06 per share while GILD was up 0.76% to $66.45 on Tuesday afternoon.
What does it mean for NuCana?
NuCana (NCNA) sued Gilead Sciences Ireland UC and Gilead Sciences GmbH in the German Regional Court of Dusseldorf, claiming GILD infringed on patents for the sale of Sovaldi and its combination products Harvoni, Vosevi and Epclusa in Germany.
NuCana announced the legal action in a SEC Form 6-K filing on April 16. The European Patent Office’s Opposition Division on April 7 upheld NuCana’s patent claim on Sovaldi, a Hepatitis C drug manufactured by the U.S.-based Gilead.
NCNA has a Fundamental Rank of 87. Find out what this means to you and get the rest of the rankings on NCNA!
NuCana PLC is a biopharmaceutical company focused on improving treatment outcome for cancer patients by ProTide technology. Utilising proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. Geographically operates through the region of the United States.